Citations (12)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Yijian Li, Qianqian Gao, Huan Liu, Shufen Lin, Huanyi Chen, Renpeng Ding, Ying Gu, Cheng-chi Chao & Xuan Dong. (2021) The Targeting Effect of Cetuximab Combined with PD-L1 Blockade against EGFR-Expressing Tumors in a Tailored CD16-CAR T-Cell Reporter System. Cancer Investigation 39:4, pages 285-296.
Read now
Read now
Jason J. Lohmueller, James D. Ham, Michael Kvorjak & Olivera J. Finn. (2018) mSA2 affinity-enhanced biotin-binding CAR T cells for universal tumor targeting. OncoImmunology 7:1.
Read now
Read now
Articles from other publishers (10)
Piotr Celichowski, Marcello Turi, Sandra Charvátová, Dhwani Radhakrishnan, Neda Feizi, Zuzana Chyra, Michal Šimíček, Tomáš Jelínek, Juli Rodriguez Bago, Roman Hájek & Matouš Hrdinka. (2023) Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility. Journal of Translational Medicine 21:1.
Crossref
Crossref
Yue Huang, Mi Shao, Yiyun Wang & He Huang. (2022) Chimeric antigen receptor‐engineered adoptive cell therapy for AML: Current status and future perspectives. ImmunoMedicine 2:1.
Crossref
Crossref
Delong Liu, Juanjuan Zhao & Yongping Song. (2019) Engineering switchable and programmable universal CARs for CAR T therapy. Journal of Hematology & Oncology 12:1.
Crossref
Crossref
Quan Le, Vyncent Nguyen & Sheldon Park. (2019) Recent advances in the engineering and application of streptavidin-like molecules. Applied Microbiology and Biotechnology 103:18, pages 7355-7365.
Crossref
Crossref
Benjamin Heyman & Yiping Yang. (2019) Chimeric Antigen Receptor T Cell Therapy for Solid Tumors: Current Status, Obstacles and Future Strategies. Cancers 11:2, pages 191.
Crossref
Crossref
Dandan Xu, Guoliang Jin, Dafei Chai, Xiaowan Zhou, Weiyu Gu, Yanyun Chong, Jingyuan Song & Junnian Zheng. (2018) The development of CAR design for tumor CAR-T cell therapy. Oncotarget 9:17, pages 13991-14004.
Crossref
Crossref
David T. RodgersMagdalena MazagovaEric N. HamptonYu Cao, Nitya S. RamadossIan R. HardyAndrew SchulmanJuanjuan DuFeng WangOded SingerJennifer MaVanessa NunezJiayin ShenAshley K. WoodsTimothy M. WrightPeter G. Schultz, Chan Hyuk KimTravis S. Young. (2016) Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies. Proceedings of the National Academy of Sciences 113:4.
Crossref
Crossref
Kaiyu Liu, Xujie Liu, Zhiping Peng, Haojie Sun, Mingzhi Zhang, Jianning Zhang, Shuang Liu, Limin Hao, Guoqiu Lu, Kangcheng Zheng, Xikui Gong, Di Wu, Fan Wang & Li Shen. (2015) Retargeted human avidin-CAR T cells for adoptive immunotherapy of EGFRvIII expressing gliomas and their evaluation via optical imaging. Oncotarget 6:27, pages 23735-23747.
Crossref
Crossref
Min Soo Kim, Jennifer S. Y. Ma, Hwayoung Yun, Yu Cao, Ji Young Kim, Victor Chi, Danling Wang, Ashley Woods, Lance Sherwood, Dawna Caballero, Jose Gonzalez, Peter G. Schultz, Travis S. Young & Chan Hyuk Kim. (2015) Redirection of Genetically Engineered CAR-T Cells Using Bifunctional Small Molecules. Journal of the American Chemical Society 137:8, pages 2832-2835.
Crossref
Crossref
Usanarat Anurathapan, Ann M. Leen, Malcolm K. Brenner & Juan F. Vera. (2014) Engineered T cells for cancer treatment. Cytotherapy 16:6, pages 713-733.
Crossref
Crossref